Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,180.74 +52.95 (+1.03%) Dow
38,852.27 +176.59 (+0.46%) Nasdaq
16,349.25 +192.92 (+1.19%) Bitcoin USD
63,458.30 -215.30 (-0.34%) CMC Crypto 200
1,364.74 +52.11 (+3.97%)
VRTX Jan 2026 220.000 put
| Previous close | 2.5500 |
| Open | 4.3000 |
| Bid | 0.1000 |
| Ask | 10.0000 |
| Strike | 220.00 |
| Expiry date | 2026-01-16 |
| Day's range | 2.5500 - 4.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 9 |
ReutersVertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments
Cystic fibrosis (CF) - an inherited disorder that causes severe damage to the lungs, digestive system and other organs - affects an estimated 105,000 people across 94 countries, according to data from U.S.-based CF Foundation. Sales from Vertex's top-selling CF drug Trikafta, also sold as Kaftrio in some markets, rose more than 18% from a year earlier to $2.48 billion in the quarter, beating analysts' expectations of $2.38 billion.
Business WireVertex Reports First Quarter 2024 Financial Results
BOSTON, May 06, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2024, and reiterated full year 2024 financial guidance.
ZacksCRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
On CRISPR Therapeutics' (CRSP) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to the first sales numbers of its newly approved gene therapy, Casgevy.
